Skip to main content
. 2013 Jul 8;8(7):e69462. doi: 10.1371/journal.pone.0069462

Figure 2. Variations in cost-effectiveness results by funding source and prevention category: a) Primary CV prevention and b) Secondary CV prevention.

Figure 2

CV: Cardiovascular.

Note: Each dot represents an incremental cost (in US$) per QALY/LYG in the reviewed articles. The horizontal line represents the willingness-to-pay threshold.